The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
Ryan Joyce, Vivian W. Hu, Jun Wang
Topics & Concepts
RitonavirBioavailabilityProtease inhibitor (pharmacology)PharmacologyCoronavirus disease 2019 (COVID-19)CYP3A4DrugOral administrationMedicineMechanism (biology)VirologyViral loadVirusInternal medicineMetabolismDiseaseEpistemologyPhilosophyInfectious disease (medical specialty)Antiretroviral therapyCytochrome P450Computational Drug Discovery MethodsPharmacogenetics and Drug MetabolismSARS-CoV-2 and COVID-19 Research